Codexis, Inc. (NASDAQ:CDXS) Director Patrick Y. Yang acquired 6,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was bought at an average cost of $13.97 per share, for a total transaction of $83,820.00. Following the completion of the purchase, the director now directly owns 76,764 shares in the company, valued at approximately $1,072,393.08. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
CDXS traded down $0.30 during midday trading on Friday, reaching $13.70. The company’s stock had a trading volume of 340,322 shares, compared to its average volume of 414,270. The stock has a market cap of $788.42 million, a P/E ratio of -65.24 and a beta of -0.02. The company has a fifty day simple moving average of $15.47 and a 200 day simple moving average of $18.59. The company has a current ratio of 6.30, a quick ratio of 6.26 and a debt-to-equity ratio of 0.26. Codexis, Inc. has a twelve month low of $12.68 and a twelve month high of $23.05.
Codexis (NASDAQ:CDXS) last released its earnings results on Tuesday, August 6th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.08) by ($0.04). The business had revenue of $12.32 million during the quarter, compared to analyst estimates of $14.90 million. Codexis had a negative net margin of 23.13% and a negative return on equity of 21.60%. Sell-side analysts expect that Codexis, Inc. will post -0.21 earnings per share for the current year.
A number of research analysts recently weighed in on the company. Zacks Investment Research downgraded Codexis from a “hold” rating to a “sell” rating in a research note on Monday, August 12th. HC Wainwright reaffirmed a “buy” rating and issued a $22.50 target price on shares of Codexis in a report on Thursday, August 8th. Finally, BidaskClub lowered Codexis from a “sell” rating to a “strong sell” rating in a report on Thursday, August 15th. Two investment analysts have rated the stock with a sell rating, five have assigned a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $21.58.
Codexis Company Profile
Codexis, Inc discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services.
Featured Story: What is a recession?
Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.